| Dangerous Instrument: Political Polarization and US Civil-Military Relations R Ralston, MA Robinson PERSPECTIVES ON POLITICS, 2024 | | 2024 |
| Mechanisms of Action of the Host-Targeting Agent Cyclosporin A and Direct-Acting Antiviral Agents against Hepatitis C Virus D Liu, TP Ndongwe, J Ji, AD Huber, E Michailidis, CM Rice, R Ralston, ... Viruses 15 (4), 981, 2023 | 1 | 2023 |
| Visualization of positive and negative sense viral RNA for probing the mechanism of direct-acting antivirals against hepatitis C virus D Liu, PR Tedbury, S Lan, AD Huber, MN Puray-Chavez, J Ji, ... Viruses 11 (11), 1039, 2019 | 15 | 2019 |
| Hepatitis C virus infection increases autophagosome stability by suppressing lysosomal fusion through an Arl8b-dependent mechanism KN Jones-Jamtgaard, AL Wozniak, H Koga, R Ralston, SA Weinman Journal of Biological Chemistry 294 (39), 14257-14266, 2019 | 22 | 2019 |
| Oxford Research Encyclopedia of Politics R Ralston, RR Krebs | 1 | 2016 |
| Fast hepatitis C virus RNA elimination and NS5A redistribution by NS5A inhibitors studied by a multiplex assay approach D Liu, J Ji, TP Ndongwe, E Michailidis, CM Rice, R Ralston, ... Antimicrobial agents and chemotherapy 59 (6), 3482-3492, 2015 | 23 | 2015 |
| HCV Inhibits Lysosomal Fusion Through Altering Arl8b Function KN Jones-Jamtgaard, AL Wozniak, R Ralston, SA Weinman MOLECULAR BIOLOGY OF THE CELL 26, 2015 | | 2015 |
| HCV Inhibits Lysosomal Fusion Through Suppression of a Rab7 Interacting Protein. AL Wozniak, KN Jones-Jamtgaard, R Ralston, SA Weinman MOLECULAR BIOLOGY OF THE CELL 25, 2014 | | 2014 |
| Hepatitis C and alcohol exacerbate liver injury by suppression of FOXO3 B Tumurbaatar, I Tikhanovich, Z Li, J Ren, R Ralston, S Kuravi, ... The American journal of pathology 183 (6), 1803-1814, 2013 | 30 | 2013 |
| Genetic markers associated with interferon-alpha response A Bertelsen, J Fellay, D Ge, DB Goldstein, JG McHutchison, P Qiu, ... US Patent 8,535,887, 2013 | 15 | 2013 |
| Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies RJO Barnard, JA Howe, RA Ogert, S Zeuzem, F Poordad, SC Gordon, ... Virology 444 (1-2), 329-336, 2013 | 79 | 2013 |
| Identification of PTC725, an orally bioavailable small molecule that selectively targets the hepatitis C virus NS4B protein Z Gu, JD Graci, FC Lahser, JJ Breslin, SP Jung, JH Crona, P McMonagle, ... Antimicrobial agents and chemotherapy 57 (7), 3250-3261, 2013 | 23 | 2013 |
| Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial RA Ogert, JA Howe, JM Vierling, PY Kwo, EJ Lawitz, J McCone, ER Schiff, ... Antiviral therapy 18 (3), 387-397, 2013 | 27 | 2013 |
| Hepatitis C virus infection stabilizes autophagosomes by suppressing lysosomal fusion KN Jones, AL Wozniak, A Cuervo, R Ralston, SA Weinman MOLECULAR BIOLOGY OF THE CELL 24, 2013 | | 2013 |
| Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa‐2b J Vermehren, S Susser, CM Lange, N Forestier, U Karey, E Hughes, ... Journal of viral hepatitis 19 (2), 120-127, 2012 | 59 | 2012 |
| The conundrum of relapse in STAT-C therapy: does HCV play the Red Queen or Rip Van Winkle? R Ralston, I Jacobson, M Scull Seminars in liver disease 31 (04), 410-419, 2011 | 15 | 2011 |
| Imaging-based assay for identification and characterization of inhibitors of CXCR4-tropic HIV-1 envelope-dependent cell-cell fusion S Kramer, P Buontempo, S Agrawal, R Ralston Journal of Biomolecular screening 16 (6), 668-675, 2011 | 7 | 2011 |
| Observed in Patients Infected With HCV Genotype 1A/lb When Treated With Boceprevir Plus Peginterferon Alfa-2B/Rihavirin CA Brass, RJ Barnard, JA Howe, RA Ogert, R Ralston, N Boparai, ... GASTROENTEROLOGY 140 (5), S942-S943, 2011 | | 2011 |
| Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG AD Kwong, I Najera, J Bechtel, S Bowden, J Fitzgibbon, P Harrington, ... Gastroenterology 140 (3), 755-760. e12, 2011 | 42 | 2011 |
| Presence of Baseline Boceprevir (Boc) Resistance-Associated Variants (Ravs) Appears Not to Influence Treatment Outcomes in the Majority of Patients Following Boc/PR Treatment RA Ogert, P Mendez, JK Albrecht, CA Brass, J Long, JA Howe, R Ralston, ... Gastroenterology 5 (140), S-946, 2011 | | 2011 |
Michael HoughtonVerified email at ualberta.ca